ODOMZO (Sonidegib)

Fact of Medicine

  • Name: Odomzo
  • Innovator Brand Name: Odomzo
  • API: Sonidegib
  • Packaging: 30 Capsules
  • Strength: 200mg
  • Manufacturer Name: Sun Pharma
Get Price
Categories: ,


Odomzo 200 mg(Sonidegib Capsules)

(ODOMZO is a registered trademarks Novartis Pharmaceutical Corporation)

What is ODOMZO:

ODOMZO is a medicine that contains the active substance Sonidegib and is available as Capsules.

Odomzo – Sonidegib 200 mg is supplied for Tenders, Emergency imports, Orphan drug, Reference listed drugs, Comparator Drug, Name patient medicine, Bio-Similar and Innovator samples etc

Uses of medication: Odomzo (sonidegib) is used in order to treat adult patients with locally advanced BCC (Basal Cell Carcinoma) that has recurred after the surgery/radiation therapy, or those who are not recipients for the surgery/radiation therapy.

Dosage: Odomzo should be taken exactly as your healthcare provider instructs you. The recommended odomzo dose is 200 mg, should be taken by mouth once in a day on an empty stomach, at least 1-hour prior to or 2-hours following a meal, administered until disease progression or unacceptable toxicity. In case a dose of odomzo 200 mg is missed, dosing should be resumed with the next scheduled dose.

Treatment Reactions: The most commonly reported sonidegib side effects include:

  • Hair loss
  • Change in taste
  • Tiredness
  • Itching
  • Nausea
  • Diarrhea
  • Weight loss
  • Decreased appetite
  • Vomiting
  • Stomach area (abdominal) pain

Warnings and Precautions

  • Odomzo 200 mg can be responsible for causing absence of menstrual periods (amenorrhea) in females who are able to become pregnant. It is unspecified if amenorrhea is permanent. Discuss with your doctor in case you have any concerns about fertility.
  • It is not recommended to donate blood or blood products while on the treatment with odomzo medication and for 20-months following the last dose.
  • Avoid donating semen while taking treatment with odomzo capsules and for at least 8-months following the final dose.
  • Women with childbearing potential should avoid taking treatment with sonidegib.
  • Breastfeed should be avoided during treatment and for 20-months after the last dose of odomzo 200 mg. Talk to your doctor about the best way in order to feed your baby during this time.

More Info.

Availability in India:

The Indian Pharma (TIP) helps connect buyers with suppliers who can ship ODOMZO at the global level as per the need of buyer’s. The Indian Pharma provides guarantee of the quality and delivery for the ODOMZO Capsules.

Buying Procedure: In order to buy ODOMZO, you can contact us at our Toll-free number 1800 889 1064 or on WhatsApp number +919310090915 or an Email to us at: info@theindianpharma.com along with the patient’s Identity Proof, Valid Prescription Letter and Medical Reports.

Conclusion: Treatment with Sonidegib (Odomzo) has demonstrated the long term efficacy as well as safety and has become an important treatment option for patients with advanced BCC.

Commonly Asked Questions

What does Odomzo contain as an active substance?

The odomzo medication specifically contains the active substance Sonidegib.

From which class of drug Sonidegib belongs?

Sonidegib basically belongs to a class of drug named biphenyl carboxamides.

How does Sonidegib act?

As a Hedgehog pathway inhibitor, sonidegib helps in order to block the molecular pathway, active in locally advanced BCC. It binds to and inhibits Smoothened, a protein involved in the Hedgehog pathway. In order to suppress the Hedgehog pathway, sonidegib blocks or resist the growth of cancer lesions.

How much does odomzo cost?

The odomzo price may vary depending on the pharmacy you visit. The cost for Odomzo oral capsule 200 mg is around 892,800 INR for a supply of 30 capsules.

Where can I get Sonidegib at the best price?

In order to get the best sonidegib price, always buy this medication from a such Pharmaceutical Wholesaler Company which is ISO and WHO-GDP certified.

Can I get sonidegib (Odomzo) even if I am not based in India?

The Indian Pharma helps patients in accessing or importing sonidegib (Odomzo), not approved in their home country against the legitimate prescription and in conformity with the all local laws and regulations of their home country.

In how many countries ODOMZO is approved for marketing?

ODOMZO is available/approved in USA and Europe. We can help you to access it in India.

What is ODOMZO used for?

Odomzo is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.

How can I get ODOMZO in India?

ODOMZO is a prescription only drug and is not approved for marketing in India.

The Indian Pharma (IP) is a consulting pharmaceutical company which assists Patients in accessing medicines in India. The Indian Pharma facilitates such access only against valid prescriptions in conformity with all local laws and regulations.

How do I contact The Indian Pharma?

Patients/ Clinicians / Researchers can contact IP at Toll free -1800 889 1064 or write to at –info@theindianpharma.com

We facilitate by-

  • Helping in documentation to import the medicine for personal use
  • Finding Genuine and reliable source in USA, Europe and Japan
  • Ensuring 100% transparency.

ODOMZO can be shipped to Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Jaipur, Lucknow, Cochin and Pune and other cities in India.

The Indian Pharma can facilitate the supply of ODOMZO (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement.

The Indian Pharma does not manufacture, supply, re-sell or retail any drugs or medicines. All trademarks and other intellectual property in relation to drugs and medicines supplied to you by suppliers are owned by their respective manufacturers or licensees

Can I get ODOMZO even if I am not based in India?

Almost all countries across the world have provisions for granting access to drugs prior to marketing approval for personal use for patients who have exhausted all other treatment options available in their country

The Indian Pharma (IP) can help patients in accessing/importing ODOMZO, unapproved in their home country against a legitimate prescription and in conformity with all local laws and regulations of their home country.

How is ODOMZO used?

ODOMZO should be administered under the guidance of specialist doctor having experience in managing cancer treatments. Recommended dose: 200 mg orally once daily taken on an empty stomach, at least 1 hour before or 2 hours after a meal. If the patient develops certain serious side effects then doctor may interrupt or stop treatment, or reduce the dose. See the summary of product characteristics on company official website for more information

Are there any side-effects/ adverse reactions/precautions associated with treatment with ODOMZO?

It is recommended to seek your doctor’s medical advice about side effects.


What information do you need to help patient in assisting documentation for ODOMZO import for personal use?

We will require the following documents to help in documentation for Named-Patient import

  • Doctor’s Prescription – We would require prescription from Registered Medical Practitioner Stating Product name, dosage, duration of treatment and diagnosis
  • Patient’s Medical history – We would require all test reports and Medical reports of the patient for last 3 months.
  • Patient’s Identity card – We will require scan copy of Patient’s identity card and proof of residence to initiate documentation process. You can use copy of Passport, Driving License, Employee ID card or any Photo ID document as your Identity card.

Send your inquiry to find Odomzo 200 mg(Sonidegib Capsules) in South East Asia – China (Beijing, Chongqing, Shanghai, Tianjin and Shenzhen), Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong, United Arab Emirates – Iraq, Iran, Saudi Arabia, Jordan, North America – Mexico, South America – Argentina, Brazil, Chile, Colombia, Peru, Venezuela, Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia, Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe, Australia and New Zealand.